Robert Edwards'  Instablog

Robert Edwards
Send Message
Contrarian daytrading technician who specializes in micro scalping of stocks (using 1 minute bar charts), swing trading of stocks overnight, weekly stock option premium selling, pre-market and post-market psuedo market maker and stealth trading activity, and selling commodity option strangles... More
  • Biotech Stocks (HALO & MYGN) Look Poised For A Rebound 0 comments
    Mar 30, 2014 10:40 PM | about stocks: HALO, MYGN

    Monday is the last day of March and the end of a quarter that has finally seen a correction in several momentum names including the very hot biotech sector. Biotech stocks have corrected for 4 to 6 weeks, depending on the company. Odds favor ending the losing streak this coming week or definitely the week after that. Despite the severe $43 selloff from its recent high, JAZZ Pharmaceuticals, Inc. (NASDAQ:JAZZ) closed Friday at $133.46, over $33 above the 50 week moving average of $100.75. It remains a leader. Gilead Sciences, Inc. (NASDAQ:GILD) has only closed down 4 weeks but the $68.55 close is just $2.70 above the 50 week moving average. Halozyme Therapeutics, Inc., (NASDAQ:HALO) closed Friday at $12.11, which was significantly above the $11.28 low of the week, and above the 50 week moving average of $10.90. Celgene (NASDAQ:CELG) has fallen for 6 straight weeks and 9 of the last 11 weeks, and at $139.29, it ended $6.60 below the 50 week moving average of $145.89. But even CELG could find support soon around $130.00. The last significant correction that occurred in CELG happened in April 2012, where is also dropped for 11 weeks, and fell 26.7% from $80.42 down to $58.53. The recent high in CELG was $174.66 and a similar correction of 26.7% would project a low of $128.03, about $11 lower than Friday's close. In both time and price, a low in the Biotech stocks appears near.

    I have already written articles about HALO, but this weekend I came across another stock in the sector that looks quite promising: Myriad Genetics, Inc. (NASDAQ:MYGN). Working in molecular diagnostics, MYGN earns $2.32 and trades at a P/E ratio of 14.20. Here is a daily chart of MYGN, showing how it recently rallied from $20.02 to a high of $39.15, in just 8 weeks:

    (click to enlarge)

    This stock has been in a 5 week downtrend since topping out at $29.15, but has only corrected 18%. It is looking like the stock may hold $32 support, but if it is broken, it should not trade below $30, before retesting the highs. There is a weekly gap between $27.18 and $29.10 that should also lend further support on any corrections into that gap beginning at $29.10. I plan to buy some shares of the stock in the low $32s and add down to $29 to $30 should the correction continue longer, in hopes of selling out possibly on a retest of the recent highs.


    The thoughts and opinions in this article, along with all stock talk posts made by Robert Edwards, are my own. I am merely giving my interpretation of market moves as I see them. I am sharing what I am doing in my own trading. Sometimes I am correct, while other times I am wrong. They are not trading recommendations, but just another opinion that one may consider as one does their own due diligence.

    Disclosure: I am long HALO.

    Stocks: HALO, MYGN
Back To Robert Edwards' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.